Brain SPECT scans predict treatment outcomes in patients with depression

New research from the Amen Clinics shows that brain SPECT (single photon emission computed tomography) imaging, a study that measures blood flow and activity patterns, identifies who is likely to get better from depression and who is not. The study is published in the Journal of Alzheimer's Disease, because depression is a highly treatable risk for cognitive decline and Alzheimer's disease.

The researchers compared the SPECT scans of 507 depressed patients who responded to treatment to the scans of 106 patients who were considered non-responders.  The study found that patients who did not respond to treatment had lower overall cerebral blood flow, especially in the frontal, temporal, and parietal lobes and in brain regions known to be affected by Alzheimer's, including the right hippocampus and left precuneus.  

Lead author psychiatrist Daniel G. Amen, MD says, "This is a critically important study.  Knowing who is likely to get better from depression and who is not, will help treating physicians be sensitive to which patients are likely to need more help and need to be monitored more closely."  Treatment resistant depression is a major risk factor for suicide, divorce, and job loss.  Dr. Amen also says, "This finding will also lead to more personalized treatment.  For patients with low brain activity, stimulating the brain will be more important, than standard serotonin enhancing drugs that tend to lower brain activity."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Small brain-penetrating molecule offers hope for treating aggressive brain tumors